Trial Profile

Phase 2 investigator-initiated randomized, placebo-controlled BOX study to evaluate the effects of twice daily administration of TNX-1900 on bone measures in children with Autism Spectrum Disorder

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 New trial record
13 Nov 2023 According to Tonix Pharmaceuticals media release, Tonix is providing active drug and placebo for the BOX study as part of a drug donation agreement with MGH. MGH is the sponsor of the trial, which is being conducted under an investigator-initiated investigational new drug (IND) application, This is a Department of Defense-funded study
13 Nov 2023 According to Tonix Pharmaceuticals media release, the first participant was enrolled in this investigator-initiated Phase 2 study of TNX-1900 at Massachusetts General Hospital (MGH).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com